NEI Research News

Researchers who work with tiny drug carriers known as lipid nanoparticles have developed a new type of material capable of reaching the lungs and the eyes, an important step toward genetic therapy for hereditary conditions like inherited vision loss.

By adapting virus-like particles to carry the machinery for a type of gene editing called prime editing, scientists have corrected disease-causing mutations in animals and increased editing efficiency.

Researchers at Indiana University School of Medicine are using a novel approach to hopefully develop a new therapy for glaucoma, a complex disease that eventually leads to blindness.

Findings from a pioneering study reveal that administration of the neuropeptide α-melanocyte–stimulating hormone (α-MSH) promotes corneal healing and restores normal eye function.

The September 14 workshop brought together multidisciplinary experts in extracellular vesicles – cell-secreted nanoparticles that mediate cell-cell communication.

A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy.

Ribosomal protein genes that are found at low levels in adult nerve cells may be very important to axon regeneration.

Members of the National Eye Institute's Audacious Goals Initiative (AGI) published an outline of milestones to reach before commencing clinical trials of regenerative therapies for retinal disease.

UConn School of Medicine researchers report that a small population of nerve cells exist in everyone that could be coaxed to regrow, potentially restoring sight and movement after injury.

The National Eye Institute has published "Stem cell sources and characterization in the development of cell-based products for treating retinal disease: An NEI town hall report."